Hormonal
Utilization of Glucagon-like peptide-1 (GLP-1) receptor agonists for Type 2 Diabetes is a significant independent predictor of achieving relevant weight loss (≥7%) in MASLD patients, with odds ratios increasing for greater weight loss thresholds.
If you have MASLD and Type 2 Diabetes, using a GLP-1 agonist significantly increases your chances of losing enough weight to improve your liver health. The data shows that users are over 4 times more likely to lose 10% or more of their body weight compared to non-users. Discuss this option with your doctor as part of a comprehensive MASLD management plan.
The utilization of GLP‐1 agonists was significantly associated with an increased likelihood of weight loss, with an OR of... 1.85 (95% CI: 1.19–3.80) of losing at least 7% and 4.22 (95% CI: 1.84–9.70) of losing at least 10%.
Why this rating
Retrospective observational data; while the association is strong, it is not a randomized controlled trial of the drug itself for weight loss in MASLD.
Source
Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
Nicola Pugliese et al. · United European Gastroenterology Journal · 2025
DOI 10.1002/ueg2.70055
More from this paper
- In patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), achieving a baseline Body Mass Index (BMI) of 30 kg/m² or higher is a significant independent predictor of achieving clinically relevant weight loss (≥7% of initial body weight) through lifestyle interventions.Good
- Engagement with a nutritionist is a significant independent predictor of achieving relevant weight loss (≥7% and ≥10%) in MASLD patients, even when controlling for baseline BMI and other comorbidities.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →